Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

Pharmacies currently making copycat versions of Eli Lilly’s tirzepatide face heightened exposure to state enforcement actions ...

The FDA urges healthcare professionals to stop administering the products, and patients should stop using them.

A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...

Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). “This was a safety-related labeling change for the glucagon-like peptide 1 receptor ...

Less than a week after the U.S. Food & Drug Administration (FDA) determined that the shortage of the tirzepatide injection, a glucagon-like peptide ...

Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...

Under US law, compounding pharmacies can make and sell patent-protected drugs that are on the FDA's shortages list in limited ...

Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...

The new contract will establish new standards that may be used to enhance specificity and sensitivity across industry assay ...

After years of ongoing shortages due to their growing popularity, all doses of both Ozempic and Wegovy are now listed as ...